Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastati...
Gespeichert in:
| Veröffentlicht in: | Case reports in oncology 2018-01, Vol.11 (1), p.17-20 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 20 |
|---|---|
| container_issue | 1 |
| container_start_page | 17 |
| container_title | Case reports in oncology |
| container_volume | 11 |
| creator | Schwab, Katjana S. Kristiansen, Glenn Schild, Hans H. Held, Stefanie E.A. Heine, Annkristin Brossart, Peter |
| description | Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab. |
| doi_str_mv | 10.1159/000485562 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000485562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_af56c7c0dae948ba8dee48309c4f1132</doaj_id><sourcerecordid>2117196992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-5842a71366f0440a3123f85d407ea47f57860cdc8390901ce6dc99e748a7a2fd3</originalsourceid><addsrcrecordid>eNptkU1P3DAQhiPUCijlwL2qLPXEYVs7sR37UglFpayEQAJ6tmbt8W6WJF7shIp_3-xHtyD1ZHv86Hk9niw7Y_QrY0J_o5RyJYTMD7JjJmU-kaIU717tj7IPKS0plVpIcZgd5VowwSk_zpb3g7WYkh8a8hAR-ha7ngRP7tBHsH2IL-T-aYA2DIlU2DSkgs5iXCP9AskVgiPQOXKD9pH8rvsFuamfQzO0MNvUp6u6qdv18WP23kOT8HS3nmS_Ln88VFeT69uf0-riemLHJvqJUDyHkhVSeso5hYLlhVfCcVoi8NKLUklqnVWFppoyi9JZrbHkCkrIvStOsunW6wIszSrWLcQXE6A2m0KIcwOxr22DBryQtrTUAWquZqAcIlcF1ZZ7xop8dH3fulbDrEVnx8-J0LyRvr3p6oWZh2cjVCGZXgu-7AQxPA2YerMMQ-zG_k3OWMm01BvqfEvZGFKK6PcJjJr1iM1-xCP7-fWT9uTfmf6LfIQ4x7gHqrvbrcKsnB-pT_-ldil_AOUutg8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2117196992</pqid></control><display><type>article</type><title>Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Karger Open Access</source><creator>Schwab, Katjana S. ; Kristiansen, Glenn ; Schild, Hans H. ; Held, Stefanie E.A. ; Heine, Annkristin ; Brossart, Peter</creator><creatorcontrib>Schwab, Katjana S. ; Kristiansen, Glenn ; Schild, Hans H. ; Held, Stefanie E.A. ; Heine, Annkristin ; Brossart, Peter</creatorcontrib><description>Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab.</description><identifier>ISSN: 1662-6575</identifier><identifier>EISSN: 1662-6575</identifier><identifier>DOI: 10.1159/000485562</identifier><identifier>PMID: 29515404</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Anti-CTLA4 antibody ; Anti-PD-1 inhibitor ; Anti-programmed cell death protein 1 inhibitor ; Cancer therapies ; Case Report ; Case reports ; Cell death ; Chemotherapy ; Clinical trials ; Enzymes ; FDA approval ; Head & neck cancer ; Hepatitis ; Immunotherapy ; Ipilimumab ; Liver ; Lymphatic system ; Medical imaging ; Medical prognosis ; Melanoma ; Metastasis ; Monoclonal antibodies ; Nivolumab ; Patients ; Skin cancer ; Squamous cell carcinoma ; Targeted cancer therapy</subject><ispartof>Case reports in oncology, 2018-01, Vol.11 (1), p.17-20</ispartof><rights>2018 The Author(s). Published by S. Karger AG, Basel</rights><rights>Copyright © 2018 by S. Karger AG, Basel 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-5842a71366f0440a3123f85d407ea47f57860cdc8390901ce6dc99e748a7a2fd3</citedby><cites>FETCH-LOGICAL-c485t-5842a71366f0440a3123f85d407ea47f57860cdc8390901ce6dc99e748a7a2fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836192/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836192/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27612,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29515404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwab, Katjana S.</creatorcontrib><creatorcontrib>Kristiansen, Glenn</creatorcontrib><creatorcontrib>Schild, Hans H.</creatorcontrib><creatorcontrib>Held, Stefanie E.A.</creatorcontrib><creatorcontrib>Heine, Annkristin</creatorcontrib><creatorcontrib>Brossart, Peter</creatorcontrib><title>Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab</title><title>Case reports in oncology</title><addtitle>Case Rep Oncol</addtitle><description>Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab.</description><subject>Anti-CTLA4 antibody</subject><subject>Anti-PD-1 inhibitor</subject><subject>Anti-programmed cell death protein 1 inhibitor</subject><subject>Cancer therapies</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Enzymes</subject><subject>FDA approval</subject><subject>Head & neck cancer</subject><subject>Hepatitis</subject><subject>Immunotherapy</subject><subject>Ipilimumab</subject><subject>Liver</subject><subject>Lymphatic system</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Nivolumab</subject><subject>Patients</subject><subject>Skin cancer</subject><subject>Squamous cell carcinoma</subject><subject>Targeted cancer therapy</subject><issn>1662-6575</issn><issn>1662-6575</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkU1P3DAQhiPUCijlwL2qLPXEYVs7sR37UglFpayEQAJ6tmbt8W6WJF7shIp_3-xHtyD1ZHv86Hk9niw7Y_QrY0J_o5RyJYTMD7JjJmU-kaIU717tj7IPKS0plVpIcZgd5VowwSk_zpb3g7WYkh8a8hAR-ha7ngRP7tBHsH2IL-T-aYA2DIlU2DSkgs5iXCP9AskVgiPQOXKD9pH8rvsFuamfQzO0MNvUp6u6qdv18WP23kOT8HS3nmS_Ln88VFeT69uf0-riemLHJvqJUDyHkhVSeso5hYLlhVfCcVoi8NKLUklqnVWFppoyi9JZrbHkCkrIvStOsunW6wIszSrWLcQXE6A2m0KIcwOxr22DBryQtrTUAWquZqAcIlcF1ZZ7xop8dH3fulbDrEVnx8-J0LyRvr3p6oWZh2cjVCGZXgu-7AQxPA2YerMMQ-zG_k3OWMm01BvqfEvZGFKK6PcJjJr1iM1-xCP7-fWT9uTfmf6LfIQ4x7gHqrvbrcKsnB-pT_-ldil_AOUutg8</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Schwab, Katjana S.</creator><creator>Kristiansen, Glenn</creator><creator>Schild, Hans H.</creator><creator>Held, Stefanie E.A.</creator><creator>Heine, Annkristin</creator><creator>Brossart, Peter</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180101</creationdate><title>Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab</title><author>Schwab, Katjana S. ; Kristiansen, Glenn ; Schild, Hans H. ; Held, Stefanie E.A. ; Heine, Annkristin ; Brossart, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-5842a71366f0440a3123f85d407ea47f57860cdc8390901ce6dc99e748a7a2fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-CTLA4 antibody</topic><topic>Anti-PD-1 inhibitor</topic><topic>Anti-programmed cell death protein 1 inhibitor</topic><topic>Cancer therapies</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Enzymes</topic><topic>FDA approval</topic><topic>Head & neck cancer</topic><topic>Hepatitis</topic><topic>Immunotherapy</topic><topic>Ipilimumab</topic><topic>Liver</topic><topic>Lymphatic system</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Nivolumab</topic><topic>Patients</topic><topic>Skin cancer</topic><topic>Squamous cell carcinoma</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwab, Katjana S.</creatorcontrib><creatorcontrib>Kristiansen, Glenn</creatorcontrib><creatorcontrib>Schild, Hans H.</creatorcontrib><creatorcontrib>Held, Stefanie E.A.</creatorcontrib><creatorcontrib>Heine, Annkristin</creatorcontrib><creatorcontrib>Brossart, Peter</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case reports in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwab, Katjana S.</au><au>Kristiansen, Glenn</au><au>Schild, Hans H.</au><au>Held, Stefanie E.A.</au><au>Heine, Annkristin</au><au>Brossart, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab</atitle><jtitle>Case reports in oncology</jtitle><addtitle>Case Rep Oncol</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>11</volume><issue>1</issue><spage>17</spage><epage>20</epage><pages>17-20</pages><issn>1662-6575</issn><eissn>1662-6575</eissn><abstract>Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>29515404</pmid><doi>10.1159/000485562</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-6575 |
| ispartof | Case reports in oncology, 2018-01, Vol.11 (1), p.17-20 |
| issn | 1662-6575 1662-6575 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000485562 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Karger Open Access |
| subjects | Anti-CTLA4 antibody Anti-PD-1 inhibitor Anti-programmed cell death protein 1 inhibitor Cancer therapies Case Report Case reports Cell death Chemotherapy Clinical trials Enzymes FDA approval Head & neck cancer Hepatitis Immunotherapy Ipilimumab Liver Lymphatic system Medical imaging Medical prognosis Melanoma Metastasis Monoclonal antibodies Nivolumab Patients Skin cancer Squamous cell carcinoma Targeted cancer therapy |
| title | Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T05%3A48%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20Treatment%20of%20Refractory%20Squamous%20Cell%20Cancer%20of%20the%20Head%20and%20Neck%20with%20Nivolumab%20and%20Ipilimumab&rft.jtitle=Case%20reports%20in%20oncology&rft.au=Schwab,%20Katjana%C2%A0S.&rft.date=2018-01-01&rft.volume=11&rft.issue=1&rft.spage=17&rft.epage=20&rft.pages=17-20&rft.issn=1662-6575&rft.eissn=1662-6575&rft_id=info:doi/10.1159/000485562&rft_dat=%3Cproquest_cross%3E2117196992%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2117196992&rft_id=info:pmid/29515404&rft_doaj_id=oai_doaj_org_article_af56c7c0dae948ba8dee48309c4f1132&rfr_iscdi=true |